EUVIMEDEUVIMED entdecken
Multizentrische Studie

Survival of the Patients With Breast Cancer Who Underwent Oncotype DX Recurrence Score Testing: Long‐Term Survival Update of a Prospective Multicenter Study in Türkiye According to Different Cut‐Offs

Enver Özkurt iD, Çetin Ordu iD, Ertan Koç iD, Erhan Gokmen, Mustafa Ozdogan, Nilufer Guler, Cihan Uras, Bahadır Öz, Orhan Demircan, Abdurrahman Isikdogan, Pinar Saip, Vahit Ozmen iD

World Journal of Surgery · 2025

DOI: 10.1002/wjs.70025 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift World Journal of Surgery, 2025. Verfasst von Enver Özkurt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Faculty of Medicine, Demiroğlu Bilim University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Seventy percent of early‐stage breast cancers are hormone receptor positive. In this prospectively designed study, we aim to update the long‐term survival outcomes of chemotherapy decision‐making according to Oncotype DX Recurrence Score (ODX‐RS) and its relation with different cut‐offs. Materials and Methods Ten academic centers in Türkiye that routinely discuss all new cases at multidisciplinary tumor board participated. Consecutive patients who are pT1–3, pN0‐N1mic, M0 were identified. Adjuvant treatment decisions were discussed at tumor board before and after ODX‐RS results.

Results

Of the 165 patients (26–76, median 48 years) with a median follow‐up of 108 months, ODX‐RS ≤ 25 had significantly better overall survival (OS) than those with ODX‐RS ≥ 26 ( p = 0.022). When evaluated by age, OS and disease‐free survival (DFS) was significantly better with ODX‐RS ≤ 15 in patients aged ≤ 50 years and with ODX‐RS ≤ 25 in patients aged > 50 years ( p = 0.034 and p = 0.024). ODX‐RS ≤ 20 in patients aged ≤ 50 years and ODX‐RS ≤ 25 in patients aged > 50 years had significantly better OS ( p = 0.002). There was no difference in OS between those who received chemotherapy before ODX‐RS and those who did not ( p = 0.119). Conversely in the post‐ODX‐RS, ODX‐RS predicted survival better and OS was lower in patients who received chemotherapy compared to those who did not ( p = 0.020) meaning that ODX‐RS can predict OS. The ODX‐RS test significantly reduced overall chemotherapy‐related costs, yielding a favorable ICER of $3787.5 per QALY gained, thus demonstrating its cost‐effectiveness.

Conclusions

The ODX‐RS significantly influences treatment decisions resulting comparable survivals for patients who received chemotherapy and who did not. Different cut‐offs have variable significant prognostic effect on survival prediction models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMiddle AgedAgedProspective StudiesAdultChemotherapy, AdjuvantSurvival RateDisease-Free SurvivalNeoplasm StagingPrognosisFollow-Up Studies

Stichwörter der Autor:innen

breast neoplasmchemotherapy decision‐makingearly‐stage breast cancergenomic testingsurvival outcomes

Autor:innen und Institutionen

  • Department of General Surgery, Faculty of Medicine, Demiroğlu Bilim University, Istanbul, Türkiye.
  • Department of Medical Oncology, Faculty of Medicine, Demiroğlu Bilim University, Istanbul, Türkiye.
  • Biostatistics, İstanbul İstatistik Akademisi, Istanbul, Türkiye.
  • Division of Medical Oncology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Division of Medical Oncology, Department of Internal Medicine, Akdeniz University Faculty of Medicine/Memorial Hospital Antalya, Antalya, Türkiye.
  • Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Türkiye.

ORCID-Profile: Enver Özkurt, Çetin Ordu, Ertan Koç, Vahit Ozmen

Zitieren

APA

Özkurt, E., Ordu, Ç., Koç, E., Gokmen, E., Ozdogan, M., Guler, N., Uras, C., Öz, B., Demircan, O., Isikdogan, A., Saip, P., & Ozmen, V. (2025). Survival of the Patients With Breast Cancer Who Underwent Oncotype DX Recurrence Score Testing: Long‐Term Survival Update of a Prospective Multicenter Study in Türkiye According to Different Cut‐Offs. World Journal of Surgery. https://doi.org/10.1002/wjs.70025

Vancouver

Özkurt E, Ordu Ç, Koç E, Gokmen E, Ozdogan M, Guler N, et al. Survival of the Patients With Breast Cancer Who Underwent Oncotype DX Recurrence Score Testing: Long‐Term Survival Update of a Prospective Multicenter Study in Türkiye According to Different Cut‐Offs. World Journal of Surgery. 2025. doi:10.1002/wjs.70025

BibTeX
@article{zkurt2025,
  author = {Özkurt, Enver and Ordu, Çetin and Koç, Ertan and Gokmen, Erhan and Ozdogan, Mustafa and Guler, Nilufer and Uras, Cihan and Öz, Bahadır and Demircan, Orhan and Isikdogan, Abdurrahman and Saip, Pinar and Ozmen, Vahit},
  title = {Survival of the Patients With Breast Cancer Who Underwent Oncotype DX Recurrence Score Testing: Long‐Term Survival Update of a Prospective Multicenter Study in Türkiye According to Different Cut‐Offs},
  journal = {World Journal of Surgery},
  year = {2025},
  doi = {10.1002/wjs.70025}
}
Kostenlos starten →